Search results
Results from the WOW.Com Content Network
Individuals with a fatty-acid metabolism disorder are unable to metabolize this fat source for energy, halting bodily processes. [1] Most individuals with a fatty-acid metabolism disorder are able to live a normal active life with simple adjustments to diet and medications. If left undiagnosed many complications can arise.
Lipodystrophy syndromes are a group of genetic or acquired disorders in which the body is unable to produce and maintain healthy fat tissue. [ 1 ] [ 2 ] The medical condition is characterized by abnormal or degenerative conditions of the body's adipose tissue .
Bimagrumab, an experimental drug, works by inhibiting the action of myostatin, which limits the size of skeletal muscle. The drug has shown the ability to increase lean mass simultaneously to decreasing fat mass in obese humans, which is beneficial because it preserves or increases energy expenditure while reducing risks associated with excess fat.
The rare genetic disorder, known as familial chylomicronemia syndrome (FCS), prevents the body from breaking down fats and is characterized by extremely high levels of triglyceride. FCS is caused ...
Hormonal disorder due to the body's inability to properly metabolize fat; Increase in fat cells ; Enzymatic defect or a change in the surface of the cells that could prevent the breakdown of fat; Poor lymphatic drainage; Defective regulation of mitochondria in brown fat. Brown fat is responsible for causing heat in times of stress or cold.
In December 2016, a New Drug Application was filed with the US Food and Drug Administration (FDA), and in October 2017, a FDA advisory committee approved it unanimously. [65] In December 2017, the injectable version with the brand name Ozempic was approved for use by people with diabetes in the United States, [30] [66] and, in January 2018, in ...
Many lipid storage disorders can be classified into the subgroup of sphingolipidoses, as they relate to sphingolipid metabolism. Members of this group include Niemann-Pick disease, Fabry disease, Krabbe disease, Gaucher disease, Tay–Sachs disease, metachromatic leukodystrophy, multiple sulfatase deficiency, and Farber disease.
The gut microbiota, which is a population of microbes that live in the human digestive system, also has an important part in metabolism and generally has a positive function for its host. In terms of pathophysiological/mechanism interactions, an abnormal gut microbiota can play a role in metabolic disorder related obesity. [8]